These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15799126)

  • 1. Clinical experiences with testosterone therapy: prostate safety.
    Ebert T
    Aging Male; 2004 Dec; 7(4):304-11. PubMed ID: 15799126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.
    Guay AT; Perez JB; Fitaihi WA; Vereb M
    Endocr Pract; 2000; 6(2):132-8. PubMed ID: 11421528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
    Ebert T; Jockenhövel F; Morales A; Shabsigh R
    Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL; Morgentaler A
    J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Testosterone and the prostate].
    Sperling H; Rossi R; Lümmen G; Rübben H
    Urologe A; 2004 Sep; 43(9):1092-6. PubMed ID: 15368045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
    Morales A; Black AM; Emerson LE
    BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
    Shoskes DA; Barazani Y; Fareed K; Sabanegh E
    Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer.
    Balbontin FG; Moreno SA; Bley E; Chacon R; Silva A; Morgentaler A
    BJU Int; 2014 Jul; 114(1):125-30. PubMed ID: 25101359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement.
    El-Sakka AI; Hassoba HM; Elbakry AM; Hassan HA
    J Sex Med; 2005 Mar; 2(2):235-40. PubMed ID: 16422891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of gonadotropin and testosterone treatments on prostate volume and serum prostate specific antigen levels in male hypogonadism.
    Ozata M; Bulur M; Beyhan Z; Sengül A; Saglam M; Turan M; Corakci A; Ali Gundogan M
    Endocr J; 1997 Oct; 44(5):719-24. PubMed ID: 9466329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of androgen deficiency and replacement on prostate zonal volumes.
    Jin B; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone replacement therapy and prostate cancer: a word of caution.
    Brand TC; Canby-Hagino E; Thompson IM
    Curr Urol Rep; 2007 May; 8(3):185-9. PubMed ID: 17459266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Testosterone therapy: indications and risks].
    Maatje MGF; Dinkelman-Smit M; Boellaard WPA; Dohle GR
    Ned Tijdschr Geneeskd; 2018; 162():D1947. PubMed ID: 29303101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.